Physician profile
Stanislaus Opalacz
NPI 1215995238
$1,453.17
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167 · 2020: $112 · 2021: $593 · 2022: $565 · 2023: $15.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $297.36 | 2021-2022 | |
| Janssen Biotech, INC. | $207.21 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $190.17 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $141.84 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $136.28 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $99.52 | 2021 | |
| Allergan, INC. | $90.62 | 2019-2020 | |
| Boston Scientific Corporation | $75.63 | 2021 | |
| Gilead Sciences, INC. | $59.90 | 2019-2022 | |
| Pentax of America, INC. | $55.67 | 2022 | |
| Qol Medical, LLC | $49.76 | 2022 | |
| Celgene Corporation | $33.26 | 2021-2022 | |
| Lucid Diagnostics INC. | $15.95 | 2023 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanislaus Opalacz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.